Blueprint
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of May 2017
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X
Form
40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __ No
X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule
12g3-2(b): 82-_____________
22 May 2017 07:00 BST
ASTRAZENECA ENTERS AGREEMENT
WITH RECORDATI FOR SELOKEN
IN EUROPE
Agreement expands the commercial potential of Seloken in European
markets
AstraZeneca to receive upfront payment, plus ongoing income for
established
heart medicines
AstraZeneca announced today that it has entered into an agreement
with Recordati S.p.A (Recordati) for the commercial rights
to Seloken/Seloken ZOK (metoprolol tartrate and metoprolol
succinate respectively) and associated Logimax fixed-dose combination
(metoprolol
succinate and
felodipine) treatments in Europe. Metoprolol succinate is a
beta-blocker for the control of hypertension, angina and heart
failure.
Recordati
will pay AstraZeneca $300 million upon completion of the agreement.
AstraZeneca will also receive sales-related income through tiered
royalties, initially at a double-digit percentage of sales.
AstraZeneca will manufacture and supply the medicines to Recordati
under a supply agreement.
Mark
Mallon, Executive Vice President, Global Product & Portfolio
Strategy at AstraZeneca, said:
"This agreement allows us to concentrate our resources on
bringing multiple new medicines to patients. Recordati's expertise
in cardiovascular disease and established European salesforce will
help to expand the commercial potential of the Seloken brands, which are mature
medicines for the new AstraZeneca."
Financial considerations
In
2016, Product Sales for the Seloken brands and Logimax were $110
million in Europe. AstraZeneca will continue to commercialise the
medicines in all other markets, where it holds the rights. The
transaction is expected to complete in the second quarter of 2017,
subject to customary closing conditions and regulatory clearances.
Based on the level of ongoing interest AstraZeneca will retain in
the brands in Europe, the $300 million upfront and tiered royalties
will be reported as Other Operating Income in the Company's
financial statements. The agreement does not impact the Company's
financial guidance for 2017.
About Seloken
Seloken (metoprolol) is indicated for the control of a range
of conditions including hypertension, angina pectoris, disturbances
of cardiac rhythm, maintenance treatment after myocardial
infarction and functional heart disorders with palpitations. It is
available in European markets under brand names including
Seloken, Seloken ZOK (extended
release), Selo-Sok and Betaloc
ZOK. Logimax is the
fixed-dose combination of metoprolol succinate with felodipine.
It is indicated for the control of
hypertension.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three main therapy areas - Oncology, Cardiovascular &
Metabolic Diseases and
Respiratory. The Company also is selectively active in the areas of
autoimmunity, neuroscience and infection. AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. For more information, please
visit www.astrazeneca.com and
follow us on Twitter @AstraZeneca.
Media
Enquiries
|
|
|
Esra
Erkal-Paler
|
UK/Global
|
+44 203
749 5638
|
Karen
Birmingham
|
UK/Global
|
+44 203
749 5634
|
Rob
Skelding
|
UK/Global
|
+44 203
749 5821
|
Jacob
Lund
|
Sweden
|
+46
8 553 260 20
|
Michele
Meixell
|
US
|
+1 302
885 2677
|
Investor
Relations
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203
749 5712
|
Craig
Marks
|
Finance,
Fixed Income, M&A
|
+44
7881 615 764
|
Henry
Wheeler
|
Oncology
|
+44 203
749 5797
|
Mitchell
Chan
|
Oncology
|
+1 240
477 3771
|
Lindsey
Trickett
|
Cardiovascular
& Metabolic Diseases
|
+1 240
543 7970
|
Nick
Stone
|
Respiratory
|
+44 203
749 5716
|
Christer
Gruvris
|
Autoimmunity,
Neuroscience & Infection
|
+44 203
749 5711
|
US toll
free
|
|
+1 866
381 7277
|
Adrian Kemp
Company Secretary, AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
AstraZeneca
PLC
Date:
22 May 2017
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|